GlassScriptPhysician profile
Richmond K Nuamah
NPI 1730188657
$2,230.80
in general payments reported to CMS, 2019-2025
18 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2021: $84.99 · 2022: $203 · 2023: $425 · 2024: $591 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619 · Education: $19.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.95 |
| Education | $19.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.25 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $199.24 | 2024-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $183.20 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $177.87 | 2019-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $172.34 | 2023-2025 | Lupkynis |
| Horizon Therapeutics Plc | $128.08 | 2019-2023 | Krystexxa |
| Amgen INC. | $126.97 | 2019-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $106.31 | 2019 | |
| Glaxosmithkline, LLC. | $77.61 | 2023-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $66.05 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $61.66 | 2024-2025 | Ultomiris |
| Ardelyx, INC. | $58.33 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $41.85 | 2024-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $39.28 | 2023-2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $39.19 | 2024-2025 | Velphoro, Velphoro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.68 | 2025 | |
| Mallinckrodt Hospital Products INC. | $26.66 | 2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $20.23 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richmond Nuamah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.